We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
GSTT2
HPA
RESOURCES
  • TISSUE
  • BRAIN
  • SINGLE CELL
  • SUBCELLULAR
  • CANCER
  • BLOOD
  • CELL LINE
  • STRUCTURE & INTERACTION
ABOUT
  • INTRODUCTION
  • HISTORY
  • ORGANIZATION
  • PUBLICATIONS
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • ACKNOWLEDGMENTS
  • CONTACT
NEWS
  • NEWS ARTICLES
  • PRESS ROOM
LEARN
  • DICTIONARY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
  • METHODS
  • EDUCATIONAL VIDEOS
DATA
  • DOWNLOADABLE DATA
  • PUBLICATION DATA
  • RELEASE HISTORY
HELP
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • HELP & FAQ
  • PRIVACY STATEMENT
  • LICENCE & CITATION
Fields »
Search result

Field
Term
Gene name
Class
Subclass
Class
Keyword
Chromosome
External id
Tissue
Cell type
Expression
Antibody panel
Tissue
Main location
Patient ID
Annotation
Tissue
Category
Tau score
Cluster
Reliability
Brain region
Category
Tau score
Brain region
Category
Tau score
Brain region
Category
Tau score
Cluster
Reliability
Tissue
Cell type
Enrichment
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell type
Category
Tau score
Cell lineage
Category
Tau score
Cluster
Cluster
Location
Searches
Location
Cell line
Class
Type
Phase
Reliability
Cancer
Prognosis
Cancer
Category
Cancer
Category
Tau score
Cluster
Variants
Interacting gene (ensg_id)
Type
Number of interactions
Pathway
Category
Score
Score
Score
Validation
Validation
Validation
Validation
Antibodies
Data type
Column


  • SUMMARY

  • TISSUE

  • BRAIN

  • SINGLE CELL

  • SUBCELL

  • CANCER

  • BLOOD

  • CELL LINE

  • STRUCT & INT

  • GSTT2
CANCER OVARIAN CANCER Show tissue menu
BREAST CANCER CARCINOID CERVICAL CANCER COLORECTAL CANCER ENDOMETRIAL CANCER GLIOMA HEAD AND NECK CANCER LIVER CANCER LUNG CANCER LYMPHOMA
MELANOMA OVARIAN CANCER PANCREATIC CANCER PROSTATE CANCER RENAL CANCER SKIN CANCER STOMACH CANCER TESTIS CANCER THYROID CANCER UROTHELIAL CANCER
OV TCGA OV VALIDATION PROTEIN OV CPTAC PROTEIN EXPRESSION
ANTIBODIES
AND
VALIDATION
Dictionary
Ovarian cancer
Human cancer
Ovary serous cystadenocarcinoma
OVARY SEROUS CYSTADENOCARCINOMA (TCGA) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
OVARY SEROUS CYSTADENOCARCINOMA (VALIDATION) - Interactive survival scatter ploti

The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.

The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".

Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.

Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.

& Survival analysisi

Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.

  Survival analysis data not available.
OVARY SEROUS CYSTADENOCARCINOMA - Protein relative expression (CPTAC)
Number of samples 108
Samples
Sample ID Sample type nRPX
1abbcb28-f221-4cd4-8c01-37b9bb_D1_D2 Normal 1.9
eb3f3494-7057-4afe-b212-e6e9a3_D2 Tumor 0.5
0c87932d-b6fd-4eb5-b86a-a34d07_D2 Tumor 0.5
e6850782-fd2a-4c53-b682-1852fe_D2 Tumor 0.4
21efd60f-6a31-4b98-9477-16a905_D2 Normal 0.4
51c1c79e-5a8e-4b0a-bf92-1c0cab_D2 Tumor 0.3
2ed8beb2-bc63-4bad-b5fe-1916a0_D2 Tumor 0.2
3946a96c-e0ae-442f-83b4-a9350e_D2 Tumor 0.2
80873a0c-1f40-4d51-bab1-3f2071_D2 Tumor 0.2
31c15e30-21d4-4843-bd4a-9cd0d8_D2 Normal 0.2
74a45e5a-a35a-4c60-a4b4-f3f5ea_D2 Tumor 0.2
1db5574d-aca7-403c-8100-6e705f_D2 Normal 0.1
cfd76f9a-ce60-4ec7-8e6b-a8fc31_D3 Tumor 0.1
af95e2c6-25c4-4ab8-bf06-3e15ff_D2 Tumor 0.1
a3a26070-fb84-406a-8280-d555e6_D2 Normal 0.1
6e209757-a7f4-45af-b5f3-2ebc02_D2 Normal 0.0
a65d8e76-640f-4341-a561-afbb57_D2 Normal 0.0
0745488e-0bfb-4d1f-8228-dedf76_D1_D2 Normal 0.0
b22659b9-e12c-4725-a7db-a833de_D1_D2 Normal 0.0
61f76fe6-a1c6-41b8-bdc2-2f9209_D2 Normal 0.0
2dc28da8-7ff1-4b9b-b5bd-17cc25_D2 Tumor 0.0
9c8e78bf-b03e-4ba0-9909-5ff070_D2 Tumor 0.0
9a7a86d3-bbf2-4d36-941d-c75c03_D1_D2 Tumor -0.1
3e746bea-ed68-40e6-b348-6ddf08_D2 Normal -0.1
42d860a3-8a0c-4c44-a09a-9ad8cf_D2 Tumor -0.1
15524912-685a-47ce-a824-567848_D2 Tumor -0.1
bd266bdd-12e4-42cb-9c49-911bfc_D2 Tumor -0.2
7edfd606-4bee-4529-9fec-1ca7f0_D2 Normal -0.2
994f9b8e-46cb-413f-8ec8-2c2fed_D2 Normal -0.2
b9c1f22e-61f7-45ed-b3b4-5094c7_D2 Normal -0.2
ce1e5dfc-2ef1-4633-af93-5ea4d9_D2 Tumor -0.2
50997c44-1c8b-4d34-b535-4a6cc2_D2 Tumor -0.2
256ac9f5-1e19-44b4-92fb-fef3fc_D2 Tumor -0.2
e23eb014-69c1-460a-b9d4-9786c8_D2 Normal -0.3
7c7ce2d7-6c8a-424e-8e6c-d14ad1_D2 Tumor -0.3
f6c215ea-5381-4521-bb61-be8e97_D2 Tumor -0.3
2b4ce90c-8036-4207-ac3e-54a76f_D2 Tumor -0.3
fe83e13f-9754-403b-8f74-d6caf8_D2 Tumor -0.3
8ed739dd-ae0f-4881-971a-db3cf4_D1_D2 Normal -0.4
2115808b-6a0d-49bc-a8d7-b83bde_D2 Tumor -0.4
76e77c6b-c80e-4391-bdbb-e1dcea_D2 Tumor -0.4
627e6e36-3dca-4ee5-9755-6f3510_D2 Tumor -0.4
e3ebe010-cd31-4b5d-8fcb-b7103b_D2 Tumor -0.4
161317f3-1a39-438e-af45-cd2502_D2 Tumor -0.4
08296da7-70ea-44df-8646-09f2cc_D2 Tumor -0.5
46c73531-f531-4ec3-97fe-b39d9d_D2 Tumor -0.5
41d0619e-b299-42e2-ac32-29e784_D2 Tumor -0.5
685ec3c2-e67a-40d3-9eb3-aa01c9_D1_D2 Normal -0.5
efc971f8-54c5-4531-a792-705ecf_D2 Tumor -0.5
6319b36b-533c-4e86-8e12-80552e_D3 Tumor -0.5
9b90eb78-2f50-4aeb-b010-d642f9_D2 Tumor -0.5
3dcf8b3c-c0c5-4dfa-9543-5d30fb_D2 Tumor -0.5
4ccb249a-6722-491e-97e9-e3b4e7_D2 Tumor -0.6
a583d3ff-8165-43e9-b764-23b7ef_D1_D2 Normal -0.6
eb0a53df-7620-4024-8d2d-051142_D2 Tumor -0.6
05387aad-2a1f-42c2-8d6f-950598_D3 Tumor -0.6
092af714-b97a-457c-b0e9-8c20e8_D2 Normal -0.6
28d0abdb-f682-4bd3-9425-a9c508_D2 Tumor -0.6
340a3769-3031-41ae-bb08-a2f696_D2 Normal -0.6
a8853382-b726-4ce8-98d5-ca89df_D2 Tumor -0.7
7d953d1d-84b6-4ecd-b1d7-1ed865_D2 Tumor -0.7
10c2d629-0287-4511-ac25-f29031_D2 Tumor -0.7
1772e913-f62e-446a-8cf3-720348_D2 Tumor -0.7
8d78194e-fbef-4819-a7b5-b73ae9_D2 Tumor -0.7
3d3e1888-d67e-4c69-ba83-112d0f_D2 Tumor -0.7
3fbf076a-824b-4eac-b6dc-bf5e59_D2 Normal -0.7
27f3ca2d-a86f-479d-8e7e-5307c7_D2 Tumor -0.7
927f0958-db5a-4bc5-92b7-2a3695_D2 Tumor -0.7
6530147a-efe9-4df6-ac2f-03ece3_D2 Tumor -0.7
1de8d3d8-fc0e-4be0-8aa7-127c7b_D2 Tumor -0.7
a03d1103-b809-42c4-ad5c-5aff58_D2 Tumor -0.7
0cc794c3-5bf5-4621-b238-58a0f6_D2 Tumor -0.8
5ea22f5e-307b-491d-801f-8b7fa6_D2 Tumor -0.8
35a345a4-e954-4c81-ae3f-7797cd_D2 Tumor -0.8
285fed94-1495-448e-879b-b55de9_D2 Tumor -0.8
2b73e01c-347a-4dae-a71d-752aeb_D2 Normal -0.8
79b60f32-6cca-4cb6-9a1e-22a3ac_D2 Tumor -0.8
e7b656bf-3c34-4ba1-bdf3-c7eefe_D2 Tumor -0.9
5c3971ee-87c7-4dff-b66e-f18892_D2 Tumor -0.9
1c9145ad-1981-4871-aa7e-8b11de_D2 Tumor -0.9
3490835c-c004-45ed-91f3-7c206f_D2 Tumor -0.9
2563cb02-d58a-4286-8634-7502cd_D2 Tumor -0.9
1556af7e-c2ae-4fce-9aae-87c459_D1_D2 Normal -0.9
49bd51fe-48a1-4828-b66e-b30c38_D2 Tumor -0.9
52c064a7-78d9-4a1a-85b4-27c6d1_D2 Tumor -0.9
2f901c90-617e-46da-9fac-d68369_D2 Tumor -0.9
1a10c200-3895-4648-b951-94f99f_D2 Tumor -0.9
558333b0-ea23-4303-9e3c-4932b1_D2 Tumor -0.9
7069e990-4a4e-4984-a66d-4d835a_D2 Tumor -0.9
8234f8ea-bdbd-45b0-bd0b-16f1e7_D2 Tumor -1.0
91b287fd-eadb-442d-abcd-20b741_D2 Tumor -1.0
3a380577-c134-47ba-a1ce-988d7c_D2 Tumor -1.0
9e0d47e0-f633-468b-b82b-4d752d_D2 Tumor -1.0
62f5840e-6cd7-4200-b651-645e53_D2 Tumor -1.0
2433b136-fc7b-4cea-b958-bc6efb_D2 Tumor -1.1
fbb41c94-aabd-49cc-90b2-882c3e_D2 Tumor -1.1
8e17b45e-6a06-4e4e-913d-7b1edb_D2 Tumor -1.1
69d552be-7cb2-4bb4-b602-a27b3e_D2 Tumor -1.1
c17b0ff9-9057-4848-a0cc-abb25f_D2 Tumor -1.1
51a4ce2f-4166-4c6b-a7e0-942d0a_D2 Tumor -1.1
347e379b-77c0-4dd3-aa25-18c9d1_D2 Tumor -1.3
e9d416e7-f661-400a-896e-388545_D2 Tumor -1.8
d38f40fb-dd78-43b2-8b7b-4b6977_D2 Tumor -1.9
2224c03f-b7b1-4368-887e-2b4cdf_D2 Tumor -2.0
1b2ab076-c72f-4bbe-b9f9-657d24_D2 Tumor -2.1
318d53c3-216b-4de1-a098-77d6dd_D2 Tumor -2.3
d4791079-c826-4fc7-9d9b-ee20ba_D2 Tumor -2.4
d109a3c0-350e-47f5-bda0-61899c_D2 Tumor -2.4
Show allShow less
OVARIAN CANCER - Protein expressioni

A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.

Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

 

Antibody stainingi

Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.

Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.


Antibody HPA000750
 Staining
  High
  Medium
  Low
  Not detected
 Intensity
  Strong
  Moderate
  Weak
  Negative
 Quantity
  >75%
  75%-25%
  <25%
  None
 Location
  Nuclear
  Cytoplasmic/membranous
  Cytoplasmic/membranous,nuclear
  None
Cystadenocarcinoma, mucinous, NOS
Carcinoma, endometroid
Carcinoma, endometroid
Cystadenocarcinoma, serous, NOS
Cystadenocarcinoma, serous, NOS

Contact

  • NEWS ARTICLES
  • PRESS ROOM

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS

The Human Protein Atlas

  • DOWNLOADABLE DATA
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg Foundation.


contact@proteinatlas.org